You Wu

Dr. You Wu

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
YWYou Wu
You Wu
YLYanping Li
Yanping Li
EGEdward Giovannucci
Edward Giovannucci

28 August 2025 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
YWYilan Wu
Yilan Wu
BQBo Qian
Bo Qian
TLTingyao Li
Tingyao Li
YQYiming Qin
Yiming Qin
ZGZhouyu Guan
Zhouyu Guan
BSBin Sheng
Bin Sheng

12 September 2022 in Health Care Science
Verified
Journal Article
Open access
YWYou Wu
You Wu
ZZZeyu Zhang
Zeyu Zhang
NZNing Zhao
Ning Zhao
YYYue Yan
Yue Yan
LZLina Zhao
Lina Zhao
ZZZongjiu Zhang
Zongjiu Zhang
Over 40 years ago, primary health care (PHC) was defined in the Alma‐Ata Declaration as a critical component of the health care system to address the basic health demand of the people. In China, the Government attaches great importance to health care at the primary level. After the launch of the historical Reform of the Medical and Health Care System in 2009, the PHC system in China has witnessed major progress and breakthroughs, especially in its steadily increased capacity, continuously improved accessibility, and betterment in equality. In this review, we summarized published literatures and official policies, synthesized data from the electronic registration information system of the National Health Commission, national statistical reports, and yearbooks in health care. The review is intended to describe the systematic development of PHC in China in the last decade. The main results include: the solid national policy foundation, increasing number of PHC institutions and workforce, better training of PHC professionals, major achievements in primary health indicators, government financial support to PHC institutions, improved PHC budgeting and insurance coverage, and the advancement of supporting technologies. Challenges and prospects are also discussed.

9 February 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
ZWZeyu Wang
Zeyu Wang
XPXin Pan
Xin Pan
HXHong Xu
Hong Xu
YWYou Wu
You Wu
XJXiaomin Jia
Xiaomin Jia
YSYang Su
Yang Su
Background: This study aimed to investigate the clinical utility of different soluble suppression of tumorigenicity 2 (sST2) levels in assessing the severity and prognosis of patients with acute heart failure (AHF).Methods: This was a prospective cohort study. Three hundred and thirty-one consecutively enrolled AHF patients from March 2018 to November 2019 were divided into 3 subgroups according to sST2 levels: T1 (1.15–7.70 ng/ml; N = 110), T2 (7.71–17.24 ng/ml; N = 111), and T3 (17.26–47.42 ng/ml; N = 110). The patients were followed up for a median period of 21.0 months for the development of the primary endpoint. Cox proportional hazards model was performed to evaluate the prognostic value of sST2 for the clinical outcomes.Results: The mean age of patients was 69 years (range, 34–93 years), and 70.4% were male. During the follow-up period, 63 participants died. Patients with higher sST2 levels had lower left ventricular ejection fraction (correlation = −0.119, P = 0.031), and higher New York Heart Association classification (correlation = 0.443, P < 0.001) and N-terminal pro-B type natriuretic peptide (NT-proBNP) levels (correlation = 0.392, P < 0.001). Higher sST2 was also associated with creatinine, urea nitrogen, hemoglobin, and left ventricular mass index. Multivariate analysis revealed that sST2 (per log unit, hazard ratio: 2.174, 95% confidence interval [CI] 1.012–4.67, P = 0.047) and NT-proBNP (per log unit, HR 2.171, 95%CI 1.169–4.032, P < 0.001) were independent risk factors for the primary outcome in all patients with AHF.Conclusion: sST2 can provide prognostic information in AHF. The higher the sST2 level in patients with AHF, the higher the incidence of cardiovascular death.

10 December 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
XFXiaoru Feng
Xiaoru Feng
ZLZeqi Liu
Zeqi Liu
XHXiaotong He
Xiaotong He
XWXibiao Wang
Xibiao Wang
CYChangzheng Yuan
Changzheng Yuan
YWYou Wu
You Wu
(1) Background: Studies have reported that COVID-19 may increase the risk of malnutrition among patients. However, the prevalence of such risk in hospitalized COVID-19 patients is uncertain due to the inconsistent use of assessment methods. (2) Methods: PubMed, Web of Science, and EMBASE were searched to identify studies on the nutritional status of hospitalized COVID-19 patients. A pooled prevalence of malnutrition risk evaluated by Nutrition Risk Score (NRS-2002) was obtained using a random effects model. Differences by study-level characteristics were examined by hospitalization setting, time of assessment, age, and country. Risk of bias was assessed using the Newcastle–Ottawa Scale. (3) Results: 53 studies from 17 countries were identified and summarized. A total of 17 studies using NRS-2002, including 3614 COVID-19 patients were included in the primary meta-analysis. The pooled prevalence of risk of malnutrition was significantly higher among ICU patients (92.2%, 95% CI: 85.9% to 96.8%) than among general ward patients (70.7%, 95% CI: 56.4% to 83.2%) (p = 0.002). No significant differences were found between age groups (≥65 vs. <65 years, p = 0.306) and countries (p = 0.893). (4) Conclusions: High risk of malnutrition is common and concerning in hospitalized patients with COVID-19, suggesting that malnutrition screening and nutritional support during hospitalization are needed.

14 August 2024 in Asia-Pacific Journal of Ophthalmology
Verified
Journal Article
Open access
XFXiaoru Feng
Xiaoru Feng
KXKezheng Xu
Kezheng Xu
MLMing-Jie Luo
Ming-Jie Luo
HCHaichao Chen
Haichao Chen
YYYangfan Yang
Yangfan Yang
DLDennis Shun-Chiu Lam
Dennis Shun-Chiu Lam
The emergence of generative artificial intelligence (AI) has revolutionized various fields. In ophthalmology, generative AI has the potential to enhance efficiency, accuracy, personalization and innovation in clinical practice and medical research, through processing data, streamlining medical documentation, facilitating patient-doctor communication, aiding in clinical decision-making, and simulating clinical trials. This review focuses on the development and integration of generative AI models into clinical workflows and scientific research of ophthalmology. It outlines the need for development of a standard framework for comprehensive assessments, robust evidence, and exploration of the potential of multimodal capabilities and intelligent agents. Additionally, the review addresses the risks in AI model development and application in clinical service and research of ophthalmology, including data privacy, data bias, adaptation friction, over interdependence, and job replacement, based on which we summarized a risk management framework to mitigate these concerns. This review highlights the transformative potential of generative AI in enhancing patient care, improving operational efficiency in the clinical service and research in ophthalmology. It also advocates for a balanced approach to its adoption.